TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27072880

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Sham electroacupuncture
Number of subjects: 54
Study: 25223266

Group type: EXPERIMENTAL
Intervention: MF59-adjuvanted trivalent subunit vaccine (aTIV)
Number of subjects: 6078

Group type: COMPARATOR
Intervention: TIV-1 (non-adjuvanted version of aTIV)
Number of subjects: 6078

Group type: COMPARATOR
Intervention: TIV-2 (split virion vaccine)
Number of subjects: 6078

Group type: EXPERIMENTAL
Intervention: All three vaccines (aTIV, TIV-1, TIV-2)
Number of subjects: 6078
Study: 22421470

Group type: EXPERIMENTAL
Intervention: Nimesulide 100 mg
Number of subjects: 47

Group type: COMPARATOR
Intervention: Tramadol chlorhydrate 100 mg
Number of subjects: 47
Study: 19079943

Group type: EXPERIMENTAL
Intervention: HCA (2 g)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: ETO (320 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: PLA (placebo)
Number of subjects: 8
Study: 17882397

Group type: EXPERIMENTAL
Intervention: Mean Blood Glucose (MBG)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Glucose Variability (SD of blood glucose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HbA(1c)
Number of subjects: 0
Study: 15179192

Group type: EXPERIMENTAL
Intervention: Intrahepatic cisplatin at 100 mg/m
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Intrahepatic cisplatin at 125 mg/m
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Cisplatin plus PVS
Number of subjects: 19

Group type: COMPARATOR
Intervention: Cisplatin alone
Number of subjects: 19
Study: 12408517

Group type: EXPERIMENTAL
Intervention: Gastric distension at 10 mmHg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Gastric distension at 12 mmHg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Gastric distension at 14 mmHg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: First 15-min period of distension
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Intragastric pressure
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Wall tension
Number of subjects: 12
Study: 9527112

Group type: EXPERIMENTAL
Intervention: Cyclandelate
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 7615781

Group type: COMPARATOR
Intervention: Inhaled beta 2 agonist alone
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Inhaled beta 2 agonist with inhaled corticosteroids
Number of subjects: 18
Study: 2375304

Group type: EXPERIMENTAL
Intervention: Cereal-based diets with milk
Number of subjects: 8

Group type: COMPARATOR
Intervention: Cereal-based diets without milk
Number of subjects: 8
Study: 319724

Group type: EXPERIMENTAL
Intervention: Colchicine
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 31162031

Group type: EXPERIMENTAL
Intervention: Rituximab (5 x 500 mg until month 18)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Azathioprine (2 mg/kg per day, gradually decreased between month 12 and 22)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 0
Study: 28454498

Group type: EXPERIMENTAL
Intervention: Citalopram 20 mg (once daily)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study: 25682524

Group type: EXPERIMENTAL
Intervention: RIME intervention (three sessions)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Brief Psychotherapy (average of six sessions)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Brief Psychotherapy (average of five sessions)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: RIME intervention
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: RIME Group
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 28
Study: 24406208

Group type: EXPERIMENTAL
Intervention: Modified Index
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard DC
Number of subjects: 0
Study: 22231013

Group type: COMPARATOR
Intervention: Intravenous human albumin (HA) 20 gr infused over 1 hour
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Oral cabergoline (Cb2) 0.5 mg per day for 7 days starting on oocyte pickup day
Number of subjects: 138
Study: 19755670

Group type: EXPERIMENTAL
Intervention: Sodium salicylate (4.5 g/day)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Intralipid plus heparin (IH)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Saline infusion (SAL)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Oral sodium salicylate (SS)
Number of subjects: 6
Study: 17456651

Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg ketorolac
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: 1 mg/kg ketorolac
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Cumulative morphine administration
Number of subjects: 37
Study: 14969370

Group type: EXPERIMENTAL
Intervention: Slot Class III composite restorations
Number of subjects: 36

Group type: COMPARATOR
Intervention: Dovetail Class III composite restorations
Number of subjects: 36
Study: 12140475

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate spray (FP), 50 microg two dose unit sprays, 4 times daily for 6 weeks
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Betamethasone sodium phosphate mouthrinse (BSP), 500 microg, 4 times daily for 6 weeks
Number of subjects: 48
Study: 10346511

Group type: EXPERIMENTAL
Intervention: Interactive Voice Recognition (IVR)
Number of subjects: 229

Group type: COMPARATOR
Intervention: Live telephone interview
Number of subjects: 229
Study: 7876615

Group type: EXPERIMENTAL
Intervention: Inactivated hepatitis A vaccine (0, 1, and 12 months schedule for adults; 0, 1, and 6; 0, 1, and 2; or 0, 1, and 12 months for children)
Number of subjects: 307
Study: 2230438

Group type: EXPERIMENTAL
Intervention: Statistical analysis methods for handling equivocal subjects
Number of subjects: 0
Study: 341952

Group type: EXPERIMENTAL
Intervention: House dust mite hyposensitization
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 14
Study: 30901440

Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplement for 90 days (treatment group)
Number of subjects: 152

Group type: COMPARATOR
Intervention: No-treatment control (control group)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Low dose Vitamin D3 supplement (treatment group)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: High dose Vitamin D3 supplement (treatment group)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplement (treatment group)
Number of subjects: 152
Study: 28608438

Group type: EXPERIMENTAL
Intervention: NUTRITION (oral nutritional supplementation enriched with leucine, vitamin D, and omega-3 fatty acids)
Number of subjects: 81

Group type: COMPARATOR
Intervention: PLACEBO
Number of subjects: 81

Group type: COMPARATOR
Intervention: Both groups (NUTRITION and PLACEBO)
Number of subjects: 81
Study: 26534930

Group type: EXPERIMENTAL
Intervention: Dopamine replacement therapy (DRT)
Number of subjects: 320

Group type: COMPARATOR
Intervention: No dopamine replacement therapy (not on DRT)
Number of subjects: 320
Study: 25175478

Group type: EXPERIMENTAL
Intervention: Depression care for people with cancer
Number of subjects: 500

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 500
Study: 23026180

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP) nasal aerosol at 320 μg/day
Number of subjects: 340

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 340
Study: 18923109

Group type: EXPERIMENTAL
Intervention: Risk behaviors including frequent public drunkenness, early age of illicit drug use, involvement in the drug economy, tattooing, injecting drugs, unprotected sex
Number of subjects: 1189

Group type: EXPERIMENTAL
Intervention: HIV, HCV, and herpes simplex virus type 2 (HSV-2) infection
Number of subjects: 1189
Study: 17967219

Group type: EXPERIMENTAL
Intervention: Levobupivacaine 0.5% (10 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Bupivacaine 0.5% (10 mg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Sufentanil 5 microg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Fentanyl 10 or 20 microg
Number of subjects: 60
Study: 15337693

Group type: EXPERIMENTAL
Intervention: Second-generation coronary stents
Number of subjects: 1228
Study: 11859651

Group type: EXPERIMENTAL
Intervention: Levocetirizine 2.5 mg
Number of subjects: 470

Group type: EXPERIMENTAL
Intervention: Levocetirizine 5 mg
Number of subjects: 470

Group type: EXPERIMENTAL
Intervention: Levocetirizine 10 mg
Number of subjects: 470

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 470
Study: 10024188

Group type: EXPERIMENTAL
Intervention: Tarnobrzeg population (rural)
Number of subjects: 2443

Group type: COMPARATOR
Intervention: Warsaw population (urban)
Number of subjects: 2443

Group type: EXPERIMENTAL
Intervention: Smokers
Number of subjects: 2443

Group type: EXPERIMENTAL
Intervention: Increase in HDL‐cholesterol (15 mg/dl)
Number of subjects: 2443
Study: 8179048

Group type: EXPERIMENTAL
Intervention: Self-help package
Number of subjects: 683

Group type: EXPERIMENTAL
Intervention: Nutrition course
Number of subjects: 683

Group type: COMPARATOR
Intervention: Screening only (control group)
Number of subjects: 683
Study: 3429102

Group type: EXPERIMENTAL
Intervention: 5-methoxy psoralen (5-MOP) PUVA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 5-MOP Re-PUVA with daily oral etretinate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 5-MOP Re-PUVA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Doses adapted to total body surface
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Emollient creams, tar gels, nonsteroidal scalp applications
Number of subjects: 0
Study: 31932084

Group type: EXPERIMENTAL
Intervention: Alirocumab 150 mg every 2 weeks
Number of subjects: 23
Study: 29549751

Group type: EXPERIMENTAL
Intervention: Monitor the CS+ (N=19)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Avoid the CS+ and attend to another stimulus (N=18)
Number of subjects: 57

Group type: COMPARATOR
Intervention: No attention manipulation control (N=20)
Number of subjects: 57
Study: 27632197

Group type: EXPERIMENTAL
Intervention: Alcohol intake (10 g ethanol per day)
Number of subjects: 156386

Group type: EXPERIMENTAL
Intervention: Exclusion of heavy drinkers and the elderly
Number of subjects: 156386

Group type: COMPARATOR
Intervention: ALDH2 variant rs671
Number of subjects: 156386
Study: 24905901

Group type: EXPERIMENTAL
Intervention: Screen-based measurement paradigms
Number of subjects: 42

Group type: COMPARATOR
Intervention: Naturalistic measurement paradigms
Number of subjects: 42
Study: 22840829

Group type: EXPERIMENTAL
Intervention: 10-week exercise intervention program consisting of supervised weekly 60-minute sessions and unsupervised 30 minutes of aerobic exercises 4 times each week.
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 10-week exercise intervention program
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 10-week exercise intervention program (exercising more than 90 minutes per week)
Number of subjects: 40
Study: 20194702

Group type: EXPERIMENTAL
Intervention: 400 mg posaconazole oral suspension twice daily for 8 days with a high-fat meal
Number of subjects: 30
Study: 18603414

Group type: EXPERIMENTAL
Intervention: Structural magnetic resonance imaging
Number of subjects: 50
Study: 16084803

Group type: EXPERIMENTAL
Intervention: Strength Training (ST)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Aerobic Endurance Training (ET)
Number of subjects: 39
Study: 12451009

Group type: COMPARATOR
Intervention: Postexercise cardiovascular dynamics in RVOTR patients
Number of subjects: 79

Group type: COMPARATOR
Intervention: Postexercise cardiovascular dynamics in control subjects
Number of subjects: 79

Group type: COMPARATOR
Intervention: Postexercise cardiovascular dynamics in patients after closure of an atrioventricular septal defect
Number of subjects: 79
Study: 10511057

Group type: EXPERIMENTAL
Intervention: 3 microCi [14C‐N‐methyl]‐erythromycin intravenously
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 1 mg midazolam intravenously
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 2 mg midazolam orally
Number of subjects: 20
Study: 8552930

Group type: EXPERIMENTAL
Intervention: Participants in Reykjavik
Number of subjects: 2202

Group type: COMPARATOR
Intervention: Participants in Sweden
Number of subjects: 2202

Group type: EXPERIMENTAL
Intervention: Participants with gastroesophageal reflux (GER)
Number of subjects: 2202

Group type: EXPERIMENTAL
Intervention: Smokers
Number of subjects: 2202
Study: 8384659

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, etoposide, vincristine, methotrexate (CEV-M)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Cyclophosphamide, doxorubicin, vincristine (CAV)
Number of subjects: 113
Study: 2429908

Group type: EXPERIMENTAL
Intervention: inosine pranobex (Imunovir)
Number of subjects: 165

Group type: COMPARATOR
Intervention: conventional treatment
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: inosine pranobex (Imunovir) with conventional treatment
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Immunological studies
Number of subjects: 165
Study: 28717826

Group type: EXPERIMENTAL
Intervention: Single-Catheter Approach (SCA)
Number of subjects: 256

Group type: COMPARATOR
Intervention: Two-Catheter Approach (TCA)
Number of subjects: 256
Study: 25844870

Group type: EXPERIMENTAL
Intervention: Super LED bed (group 2)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Triple fluorescent tube units (group 1)
Number of subjects: 200
Study: 26081179

Group type: EXPERIMENTAL
Intervention: Single maximal inhalation with breath-hold (200 μg salbutamol)
Number of subjects: 82

Group type: COMPARATOR
Intervention: 5 tidal breaths (200 μg salbutamol)
Number of subjects: 82
Study: 23292207

Group type: EXPERIMENTAL
Intervention: Exercise treatment
Number of subjects: 53

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 53
Study: 21475140

Group type: EXPERIMENTAL
Intervention: Suction lipectomy
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control
Number of subjects: 32
Study: 18971135

Group type: EXPERIMENTAL
Intervention: Bupivacaine-soaked Spongostan plus local lignocaine infiltration 1% up to 20 mL
Number of subjects: 99

Group type: COMPARATOR
Intervention: Local lignocaine infiltration 1% up to 20 mL
Number of subjects: 99
Study: 17198555

Group type: EXPERIMENTAL
Intervention: Pulmonary metastasectomy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Complete resection of lung metastases
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surgical procedures
Number of subjects: 0
Study: 12657237

Group type: EXPERIMENTAL
Intervention: Hetastarch (6% hydroxyethyl starch)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Peritoneal dialysis solution (1.5% dextrose)
Number of subjects: 20
Study: 11119198

Group type: EXPERIMENTAL
Intervention: Rectal diclofenac 2 mg.kg(‐1) following oral placebo premedication
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: i.v. flurbiprofen 1 mg.kg(‐1) following placebo premedication
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Oral clonidine premedication
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Rectal diclofenac 2 mg.kg(‐1) following clonidine
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: i.v. flurbiprofen 1 mg.kg(‐1) following clonidine
Number of subjects: 125
Study: 7546970

Group type: EXPERIMENTAL
Intervention: Ketac Fil
Number of subjects: 37

Group type: COMPARATOR
Intervention: Ketac Silver
Number of subjects: 37
Study: 2252363

Group type: EXPERIMENTAL
Intervention: Botulinum toxin (400 mouse units)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 7240113

Group type: EXPERIMENTAL
Intervention: imipramine
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: doxepin
Number of subjects: 79
Study: 31771756

Group type: EXPERIMENTAL
Intervention: Multiple barriers to adherence (e.g., forgetfulness, health beliefs)
Number of subjects: 1069

Group type: EXPERIMENTAL
Intervention: Non-white patients
Number of subjects: 1069

Group type: EXPERIMENTAL
Intervention: Single/unpartnered status
Number of subjects: 1069

Group type: EXPERIMENTAL
Intervention: Tobacco use
Number of subjects: 1069

Group type: EXPERIMENTAL
Intervention: Poor glycemic control
Number of subjects: 1069
Study: 30666367

Group type: EXPERIMENTAL
Intervention: HFNC
Number of subjects: 192

Group type: COMPARATOR
Intervention: SMO
Number of subjects: 192
Study: 27416891

Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 50

Group type: COMPARATOR
Intervention: Etanercept
Number of subjects: 50
Study: 26062024

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 6

Group type: COMPARATOR
Intervention: Standard blind trials
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Two-by-two blind trials
Number of subjects: 6
Study: 23118346

Group type: EXPERIMENTAL
Intervention: Absorb BVS in small vessels (RVD <2.5 mm)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Absorb BVS in large vessels (RVD ≥2.5 mm)
Number of subjects: 101
Study: 21646910

Group type: EXPERIMENTAL
Intervention: Lactulose 30-60 ml twice per day (GpB)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Probiotics 110 billion CFU twice per day (GpC)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: L-ornithine L-aspartate (LOLA) 6 g three times per day (GpD)
Number of subjects: 160

Group type: COMPARATOR
Intervention: No treatment (GpA)
Number of subjects: 160
Study: 19372524

Group type: EXPERIMENTAL
Intervention: Permanent housing with intensive case management
Number of subjects: 105

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 105
Study: 16761194

Group type: EXPERIMENTAL
Intervention: ezetimibe (10 mg/day for 90 days)
Number of subjects: 12

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study: 15324976

Group type: EXPERIMENTAL
Intervention: Risk information presented in vertical bars
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Risk information presented as icons
Number of subjects: 44

Group type: COMPARATOR
Intervention: Risk information presented in numbers
Number of subjects: 44
Study: 11430965

Group type: EXPERIMENTAL
Intervention: Mifepristone 200 mg and vaginal misoprostol 800 microg (used 48 hours after mifepristone)
Number of subjects: 4393

Group type: COMPARATOR
Intervention: Vaginal misoprostol inserted at 1, 2, or 3 days after mifepristone administration
Number of subjects: 4393
Study: 9468354

Group type: EXPERIMENTAL
Intervention: Neuroleptic drugs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prophylactic treatment with neuroleptics
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Noncompliance with medication
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Current drug abuse
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alcohol and substance abuse
Number of subjects: 0
Study: 8534381

Group type: EXPERIMENTAL
Intervention: Dentifrice containing 5.0% potassium nitrate, 1.3% soluble pyrophosphate, 1.5% PVM/MA copolymer and 0.243% sodium fluoride in a silica base
Number of subjects: 115

Group type: COMPARATOR
Intervention: Placebo dentifrice (0.243% sodium fluoride silica-based)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Dentifrice containing potassium nitrate, soluble pyrophosphate and PVM/MA copolymer
Number of subjects: 115

Group type: COMPARATOR
Intervention: Placebo dentifrice
Number of subjects: 115
Study: 3226418

Group type: EXPERIMENTAL
Intervention: Continuous hyperthermic peritoneal perfusion (CHPP) with an anticancer drug
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (standard treatment)
Number of subjects: 0
Study: 30889160

Group type: EXPERIMENTAL
Intervention: Endoscopic carpal tunnel release (ECTR)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Open carpal tunnel release (OCTR)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both ECTR and OCTR
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Quick Disabilities of the Arm, Shoulder and Hand (QuickDASH)
Number of subjects: 60
Study: 28504521

Group type: EXPERIMENTAL
Intervention: Higher family dinner frequency
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Lower parent dinnertime media use
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Higher dinnertime routines
Number of subjects: 160

Group type: COMPARATOR
Intervention: Parent BMI scores
Number of subjects: 160
Study: 25185603

Group type: EXPERIMENTAL
Intervention: Pseudoephedrine ER 120 mg
Number of subjects: 56

Group type: COMPARATOR
Intervention: Imipramine 25 mg
Number of subjects: 56

Group type: COMPARATOR
Intervention: Cyclobenzaprine 10 mg
Number of subjects: 56

Group type: COMPARATOR
Intervention: Tamsulosin 0.4 mg
Number of subjects: 56

Group type: COMPARATOR
Intervention: Solifenacin 5 mg
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 22037770

Group type: EXPERIMENTAL
Intervention: Cannabis use
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Cannabis dose
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Change in cannabis dose
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Greater cannabis exposure
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Reduction in cannabis use
Number of subjects: 267

Group type: COMPARATOR
Intervention: Other substance use
Number of subjects: 267
Study: 21442659

Group type: EXPERIMENTAL
Intervention: Cognitive training program (4 weeks, 3 sessions per week, 45 minutes each, using multimedia software and paper-and-pencil exercises)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Speech therapy (control group)
Number of subjects: 28
Study: 17698933

Group type: EXPERIMENTAL
Intervention: Multiple imputation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inverse probability weighting
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Doubly robust (DR) extension
Number of subjects: 0

Group type: COMPARATOR
Intervention: Extreme case analysis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hot-deck imputation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single and multiple imputation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Likelihood based methods
Number of subjects: 0
Study: 17032348

Group type: EXPERIMENTAL
Intervention: Esomeprazole, clarithromycin, tetracycline and metronidazole (ECTM group, n = 46)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Esomeprazole, bismuth subcitrate, tetracycline and metronidazole (EBTM group, n = 47)
Number of subjects: 93

Group type: COMPARATOR
Intervention: EBTM group (metronidazole-resistant strains)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: ECTM group (metronidazole-resistant strains)
Number of subjects: 93
Study: 14610494

Group type: COMPARATOR
Intervention: Aspirin challenge
Number of subjects: 23